Dexmedetomidine as a part of general anaesthesia for caesarean delivery in patients with pre-eclampsia: A randomised double-blinded trial
CONCLUSION
Administration of dexmedetomidine in doses 0.4 and 0.6 μg kg−1 h−1 was associated with haemodynamic and hormonal stability, without causing significant adverse neonatal outcome.
TRIAL REGISTRATION
Pan African Clinical Trial Registry (PACTR201706002303170), (www.pactr.org).
Source: European Journal of Anaesthesiology - Category: Anesthesiology Tags: Obstetric anaesthesia Source Type: research
More News: African Health | Anesthesia | Anesthesiology | Cardiology | Clinical Trials | Endotracheal Intubation | Heart | Hormones | Morphine | OBGYN | Pain | Perinatology & Neonatology | Pre-eclampsia | Reflex Sympathetic Dystrophy | Study